The first diagnostic test with a home collection option for COVID-19 has been authorized by the U.S. Food and Drug Administration (FDA). The FDA reissued the emergency use authorization (EUA), allowing the Laboratory Corporation of America (LabCorp) COVID-19 RT-PCT Test to enable testing of samples self-collected by patients at home, according to an FDA news release.
By using the EUA, LabCorp tests a sample collected from the patient’s nose, through a self-collection kit containing nasal swabs and saline. Patients mail their nasal sample, with an insulated package, to a LabCorp lab to be tested.
Related link: For more information about the diagnostic test with a home collection option for COVID-19, visit: https://bit.ly/2VFB3hm.